據報恆大(03333.HK)2月銷售升6.7倍至46.8億人幣 本月推1萬套現樓優惠
內媒報道,中國恆大(03333.HK)董事長許家印本周二(2月28日)主持召開集團月度工作會議,提出要在3月份推出1萬套現樓大優惠,實現第一季業績「開門紅」。
此次活動擬在260個城市同步啟動,產品涵蓋住宅、商舖和車位等不同物業類型,滿足不同群體的各種需求。
克而瑞數據顯示,恆大2月銷售金額46.8億元人民幣,按年同期升近6.7倍,按月亦升141%,遠超行業增長水平。
另今年初許家印發布了一封恆大的內部信,指過去一年,恆大地產實現了732個保交樓項目全面復工,全年累計交樓30.1萬套。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.